利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

123 条记录 (耗时 0.029 秒)

    3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists
    32.
    发明授权
    3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists 有权
    3-杂芳基-3,9-二氮杂双环[3.3.1]壬烷衍生物作为烟碱乙酰胆碱受体激动剂

    公开(公告)号：US07687523B2

    公开(公告)日：2010-03-30

    申请号：US12087004

    申请日：2007-02-09

    申请人： Dan Peters ,  Daniel B. Timmermann ,  Gunnar M. Olsen ,  Elsebet Østergaard Nielsen ,  Jeppe Kejser Christensen

    发明人： Dan Peters ,  Daniel B. Timmermann ,  Gunnar M. Olsen ,  Elsebet Østergaard Nielsen ,  Jeppe Kejser Christensen

    IPC分类号： A61K31/44

    CPC分类号： C07D471/08

    摘要： Compounds of the class 3,9-diaza-bicyclo [3.3.1]nonane derivatives. The compounds correspond to structural Formula (I): wherein Ra is hydrogen or optionally substituted alkyl and Rb is a monocyclic heteroaryl group. The compounds are useful in the treatment, prevention, or alleviation of diseases or disorders or conditions that are responsive to modulation of nicotinic acetylcholine receptors, including cognitive disorders, Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, Bipolar Disorder, obsessive compulsive disorders (OCD), narcolepsy, senile dementia, autism, Parkinson'disease, Amyotrophic Lateral Sclerosis, epilepsy, and diabetic neuropathy.

    摘要翻译： 3,9-二氮杂双环[3.3.1]壬烷衍生物的化合物。 化合物对应于结构式（I）：其中R a是氢或任选取代的烷基，R b是单环杂芳基。 这些化合物可用于治疗，预防或缓解对烟碱乙酰胆碱受体调节，包括认知障碍，阿尔茨海默病，注意力缺陷多动障碍（ADHD），Tourette综合征，双相障碍，强迫症的疾病或病症或病症 强迫症（OCD），发作性睡病，老年痴呆，自闭症，帕金森病，肌萎缩性侧索硬化，癫痫和糖尿病性神经病变。

    3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists
    35.
    发明授权
    3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists 失效
    3,9-二氮杂双环（3.3.1）壬-3-基 - 芳基甲酮衍生物作为烟碱乙酰胆碱受体激动剂

    公开(公告)号：US07855208B2

    公开(公告)日：2010-12-21

    申请号：US12160567

    申请日：2007-02-13

    申请人： Dan Peters ,  Daniel B. Timmermann ,  Gunnar M. Olsen ,  Elsebet Ostergaard Nielsen

    发明人： Dan Peters ,  Daniel B. Timmermann ,  Gunnar M. Olsen ,  Elsebet Ostergaard Nielsen

    IPC分类号： A01N43/58 ,  A01N43/60 ,  A61K31/50 ,  A61K31/495 ,  C07D241/36

    CPC分类号： C07D471/08

    摘要： This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

    摘要翻译： 本发明涉及新的二氮杂双环芳基衍生物，其在烟碱乙酰胆碱受体和单胺受体和转运蛋白的调节剂中被发现是胆碱能配体。 由于其药理学特征，本发明的化合物可用于治疗与中枢神经系统（CNS），周围神经系统（PNS），疾病或病症相关的胆碱能系统相关的疾病或障碍 平滑肌肉收缩，内分泌疾病或病症，与神经变性相关的疾病或病症，与由化学物质的滥用终止引起的炎症，疼痛和戒断症状相关的疾病或病症。

    NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINYL DERIVATIVE AND ITS MEDICAL USE
    36.
    发明申请
    NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINYL DERIVATIVE AND ITS MEDICAL USE 失效
    新的1,4-二氮杂双环[3.2.2]壬基吡啶衍生物及其医药用途

    公开(公告)号：US20090181984A1

    公开(公告)日：2009-07-16

    申请号：US12299106

    申请日：2007-05-29

    申请人： Dan Peters ,  Gunnar M. Olsen ,  Elsebet Ostergaard Nielsen ,  Daniel B. Timmermann ,  Steven Charles Loechel

    发明人： Dan Peters ,  Gunnar M. Olsen ,  Elsebet Ostergaard Nielsen ,  Daniel B. Timmermann ,  Steven Charles Loechel

    IPC分类号： A61K31/506 ,  C07D403/02 ,  A61P25/30

    CPC分类号： C07D471/08

    摘要： This invention relates to a novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its use in the manufacture of pharmaceutical compositions. The compound of the invention is found to be a cholinergic ligand at the nicotinic acetylcholine receptors.Due to its pharmacological profile the compound of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

    摘要翻译： 本发明涉及新的1,4-二氮杂双环[3.2.2]壬基嘧啶基衍生物及其在制备药物组合物中的用途。 发现本发明的化合物是烟碱乙酰胆碱受体的胆碱能配体。 由于其药理学特征，本发明的化合物可用于治疗与中枢神经系统（CNS），周围神经系统（PNS），疾病或病症相关的胆碱能系统相关的疾病或病症多种多样 平滑肌肉收缩，内分泌疾病或病症，与神经变性相关的疾病或病症，与由化学物质的滥用终止引起的炎症，疼痛和戒断症状相关的疾病或病症。

    2,5-diazabicyclo[2.2.1]heptane derivatives
    38.
    发明授权
    2,5-diazabicyclo[2.2.1]heptane derivatives 失效
    2,5-二氮杂双环[2.2.1]庚烷衍生物

    公开(公告)号：US07329754B2

    公开(公告)日：2008-02-12

    申请号：US10250765

    申请日：2002-02-28

    申请人： Dan Peters ,  Gunnar M. Olsen ,  Elsebet Ostergaard Nielsen ,  Philip K. Ahring ,  Tino Dyhring Jorgensen

    发明人： Dan Peters ,  Gunnar M. Olsen ,  Elsebet Ostergaard Nielsen ,  Philip K. Ahring ,  Tino Dyhring Jorgensen

    IPC分类号： C07D215/38 ,  C07D265/30

    CPC分类号： C07D487/08 ,  A61K31/4995

    摘要： The present invention relates to novel 2,5-diazabicyclo[2.2.1]heptane derivatives, which are found to be potent modulators of the monoamine receptors and transporters.Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

    摘要翻译： 本发明涉及新的2,5-二氮杂双环[2.2.1]庚烷衍生物，其被发现是单胺受体和转运蛋白的有效调节剂。 由于其药理学特征，本发明的化合物可用于治疗与中枢神经系统（CNS），周围神经系统（PNS），疾病或病症相关的胆碱能系统相关的疾病或障碍 平滑肌肉收缩，内分泌疾病或病症，与神经变性相关的疾病或病症，与由化学物质的滥用终止引起的炎症，疼痛和戒断症状相关的疾病或病症。

    Heteroaryl-diazabicycloalkanes
    39.
    发明授权
    Heteroaryl-diazabicycloalkanes 失效
    杂芳基 - 二氮杂双环烷烃

    公开(公告)号：US06815438B2

    公开(公告)日：2004-11-09

    申请号：US10130099

    申请日：2002-05-14

    申请人： Dan Peters ,  Gunnar M. Olsen ,  Elsebet Ostergaard Nielsen ,  Philip K. Ahring ,  Simon Feldbaek Nielsen ,  Tino Dyhring Jorgensen

    发明人： Dan Peters ,  Gunnar M. Olsen ,  Elsebet Ostergaard Nielsen ,  Philip K. Ahring ,  Simon Feldbaek Nielsen ,  Tino Dyhring Jorgensen

    IPC分类号： A61K3133

    CPC分类号： C07D471/08 ,  C07D487/04 ,  C07D487/08

    摘要： The present invention relates to novel heteroaryl-diazabicycloalkanes which are found to be cholinergic ligands at the nicotinic Acetyl Choline Receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neurodegeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

    摘要翻译： 本发明涉及在烟碱乙酰胆碱受体中被发现是胆碱能配体的新型杂芳基 - 二氮杂双环烷烃。 由于其药理学特征，本发明的化合物可用于治疗与中枢神经系统（CNS）的胆碱能系统有关的疾病或病症，与平滑肌收缩相关的疾病或病症，内分泌疾病或 与神经变性相关的疾病，疾病或病症，与由化学物质的滥用终止引起的炎症，疼痛和戒断症状相关的疾病或病症。